Pharmaceutical Company
Appears in 1 story
Drug sponsor and U.S. commercial lead for Bizengri
Patients with advanced bile duct cancer driven by a rare genetic fusion called NRG1 had nothing approved for them after chemotherapy failed. On May 8, the FDA approved Bizengri (zenocutuzumab-zbco) from Partner Therapeutics as the first drug targeting this NRG1 fusion, blocking the abnormal protein it produces, which fuels tumor growth.
Updated May 31
No stories match your search
Try a different keyword
How would you like to describe your experience with the app today?
